冠心病患者的心包积液可通过转化生长因子-β途径驱动纤维化。
Pericardial Fluid of Patients With Coronary Artery Disease Can Drive Fibrosis Via TGF-Beta Pathway.
作者信息
Fatehi Hassanabad Ali, Belke Darrell D, Gordon Paul M K, Teng Guoqi, Dundas Jameson A, Zarzycki Anna N, Turnbull Jeannine, Deniset Justin F, Fedak Paul W M
机构信息
Section of Cardiac Surgery, Department of Cardiac Sciences, Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Marlene and Don Campbell Translational Research Laboratory, Libin Cardiovascular Institute, Cumming School of Medicine, Calgary, Alberta, Canada.
出版信息
JACC Basic Transl Sci. 2024 Aug 28;9(11):1329-1344. doi: 10.1016/j.jacbts.2024.06.007. eCollection 2024 Nov.
Human pericardial fluid (PF) is a rich reservoir of biologically active markers. The acellular compartment of PF can drive cardiac fibroblast activity in vitro. This process is mediated through the transforming growth factor-β pathway. Of clinical importance, the PF of patients with coronary artery disease has an increased profibrotic capacity compared with the PF of patients without coronary artery disease.
人心包液（PF）是生物活性标志物的丰富储存库。PF的无细胞成分可在体外驱动心脏成纤维细胞活性。这一过程通过转化生长因子-β途径介导。具有临床意义的是，与无冠状动脉疾病患者的PF相比，冠状动脉疾病患者的PF具有增强的促纤维化能力。
Zotero 插件